FibroGen Inc. (NASDAQ: FGEN): Raymond James raised the stock to Market Perform from Underperform. Over the past 52 weeks, the shares have traded between $11.47 and $57.21, and they have a $21.57 price objective. Thursday’s last trade was reported at $11.47, which was down close to 5% for the day.
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT): The Goldman Sachs downgrade to Sell from Neutral included a price target cut to $10 from $17. That compares with the $32 consensus target and Thursday’s closing price of $13.84. The stock was down almost 7% in Friday’s premarket.
Janus International Group Inc. (NYSE: JBI): KeyBanc Capital Markets started coverage with an Overweight rating and an $18 price target. No consensus target for the building products giant was available. The stock popped almost 4% on Thursday to close at $14.45.
Leslie’s Inc. (NASDAQ: LESL): Loop Capital raised the pool supply giant’s stock to Buy from Hold and has a $25 price target. The consensus target is much higher at $33.36. The final Thursday trade came in at $21.60, or down over 3% for the day.
Macy’s Inc. (NYSE: M): JPMorgan upgraded the venerable retailer’s stock to Neutral from Underweight and also lifted the price target to $25 from $19. The consensus target is $19.15. The shares closed on Thursday at $21.61, up a stunning 20% after posting stellar earnings.
Magenta Therapeutics Inc. (NASDAQ: MGTA): Goldman Sachs resumed coverage with a Neutral rating and a $7 price target. The consensus target is up at $17.14. Thursday’s final trade came in at $6.07.
MKS Instruments Inc. (NASDAQ: MKSI): Citigroup resumed coverage with a Neutral rating and a $160 price target. The posted consensus price objective is $226.89. Thursday’s closing share price was $140.42.
Mosaic Co. (NYSE: MOS): HSBC Securities upgraded the stock to a Buy from Hold and also raised the price target to $39 from $27. The consensus target is $40.16. The stock closed on Thursday at $29.57, after pulling back almost 5% on the day.
Myovant Sciences Ltd. (NYSE: MYOV): Goldman Sachs resumed coverage with a Neutral rating and an $18 price target. The consensus target is up at $37.40. Thursday’s closing price was $21.28.
Nvidia Corp. (NASDAQ: NVDA): Benchmark resumed coverage of the semiconductor leader with a Buy rating and a $230 price target. That compares with the lower $200.56 consensus target and Thursday’s closing trade of $197.98, which was up almost 4% after the company posted stellar earnings.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.